News

Preclinical in-vitro and in-vivo studies of RDEA119 have demonstrated synergistic activity across multiple tumor types when RDEA119 is used in combination with other anticancer agents, including sorafenib. This

The Phase II, multi-center, randomized, double-blind, placebo-controlled study is designed to assess the safety and efficacy of multiple doses of ACE-011 in multiple myeloma patients with osteolytic bone

Nicholas Stergis, CEO of Adeona, said: “As previously announced, we are pleased to have completed our corporate name and ticker symbol change. Our primary focus is toward the

Through the collaboration, the companies plan to work together to advance innovation in the development of probiotic-enhanced nutrition bars and powdered products. Nellson’s technical expertise in the area

The decision by the German Federal Court found that CoreValve’s ReValving system for transcatheter aortic valve replacement does not infringe any of the claims of the Andersen patent

The clinical study analyzed paraffin embedded tissue samples from 476 prostate cancer patients collected at four major clinical centers in Europe and the US who had undergone radical

The Phase I trial is an open-label, dose-escalation study evaluating IPI-926 in approximately 30 to 50 patients with advanced or metastatic solid tumors. The primary objectives of the

Terms of the agreement between TomoTherapy and Hitachi Medical are being finalized. Details will be announced upon contract signing. The partnership between TomoTherapy and Hitachi Medical is expected

Under the licensing agreement, Ono is responsible for developing and commercializing subcutaneous Relistor in Japan, including conducting the clinical development necessary to support regulatory marketing approval. Progenics will